tirabrutinib

Small moleculeexperimental

Clinical trial activity

10 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
7
Phase 3
1
Phase 4
0

Earliest trial started Jun 16, 2015 (NCT02457598)

Timeline

2010s

  1. Jan 1, 2015

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2025

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC#CC(=O)N1CC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1
Mol. weight
454.49 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • tirabrutinib
  • tirabrutinib

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07104032Phase 3Nov 30, 2025Deciphera Pharmaceuticals LLC, Ono Pharmaceuticals
NCT07198087Phase 1Oct 1, 2025Ono Pharmaceuticals
NCT06940791Phase 2Oct 6, 2023Japan Clinical Oncology Group, Kyorin University, National Cancer Center, Japan, Ono Pharmaceuticals
NCT04947319Phase 2Sep 1, 2021Ono Pharmaceuticals
NCT04827589Phase 2Jul 31, 2021Gilead Sciences
NCT03100942Phase 2May 1, 2017Galapagos NV, Gilead Sciences
NCT02983617Phase 2Apr 6, 2017German CLL Study Group, Gilead Sciences
NCT02968563Phase 2Dec 13, 2016German CLL Study Group, Gilead Sciences
NCT02457559Phase 1Nov 5, 2015Gilead Sciences
NCT02457598Phase 1Jun 16, 2015Gilead Sciences
Showing 10 of 10 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Gilead SciencesFor profit6622015
Ono PharmaceuticalsFor profit4332021
German CLL Study GroupAcademic/Hospital2012016
Deciphera Pharmaceuticals LLCFor profit1012025
Galapagos NVFor profit1012017
Japan Clinical Oncology GroupAcademic/Hospital1012023
Kyorin UniversityAcademic/Hospital1112023
National Cancer Center, JapanAcademic/Hospital1012023
8 organizations
Page 1 / 1